GENSIGHT DDR 2017 VA (104/264)

GENSIGHT DDR 2017 VAGENSIGHT DDR 2017 VA (104/264)GENSIGHT DDR 2017 VA - (1/264)GENSIGHT DDR 2017 VA - (2/264)GENSIGHT DDR 2017 VA - (3/264)GENSIGHT DDR 2017 VA - (4/264)GENSIGHT DDR 2017 VA - (5/264)GENSIGHT DDR 2017 VA - (6/264)GENSIGHT DDR 2017 VA - (7/264)GENSIGHT DDR 2017 VA - (8/264)GENSIGHT DDR 2017 VA - (9/264)GENSIGHT DDR 2017 VA - (10/264)GENSIGHT DDR 2017 VA - PERSONS RESPONSIBLE (11/264)GENSIGHT DDR 2017 VA - 1.1 NAME AND POSITION OF THE PERSON RESPONSIBLE FOR THE REGISTRATION DOCUMENT - 1.2 CERTIFICATION OF THE PERSON RESPONSIBLE FOR THE REGISTRATION DOCUMENT - 1.3 NAME AND POSITION OF THE PERSON RESPONSIBLE FOR FINANCIAL INFORMATION (12/264)GENSIGHT DDR 2017 VA - STATUTORY AUDITORS (13/264)GENSIGHT DDR 2017 VA - 2.1 STATUTORY AUDITORS - 2.2 ALTERNATE STATUTORY AUDITORS (14/264)GENSIGHT DDR 2017 VA - SELECTED FINANCIAL INFORMATION (15/264)GENSIGHT DDR 2017 VA - 3.1 Selected Financial Information (16/264)GENSIGHT DDR 2017 VA - (17/264)GENSIGHT DDR 2017 VA - (18/264)GENSIGHT DDR 2017 VA - RISK FACTORS (19/264)GENSIGHT DDR 2017 VA - 4.1 RISKS RELATED TO OUR FINANCIAL CONDITION AND CAPITAL REQUIREMENTS (20/264)GENSIGHT DDR 2017 VA - (21/264)GENSIGHT DDR 2017 VA - 4.2 RISKS RELATED TO THE DISCOVERY AND DEVELOPMENT OF AND OBTAINING REGULATORY APPROVAL FOR OUR PRODUCT CANDIDATES (22/264)GENSIGHT DDR 2017 VA - (23/264)GENSIGHT DDR 2017 VA - (24/264)GENSIGHT DDR 2017 VA - (25/264)GENSIGHT DDR 2017 VA - (26/264)GENSIGHT DDR 2017 VA - (27/264)GENSIGHT DDR 2017 VA - (28/264)GENSIGHT DDR 2017 VA - (29/264)GENSIGHT DDR 2017 VA - (30/264)GENSIGHT DDR 2017 VA - 4.3 RISKS RELATED TO THIRD PARTIES (31/264)GENSIGHT DDR 2017 VA - (32/264)GENSIGHT DDR 2017 VA - (33/264)GENSIGHT DDR 2017 VA - 4.4 RISKS RELATED TO MANUFACTURING (34/264)GENSIGHT DDR 2017 VA - (35/264)GENSIGHT DDR 2017 VA - 4.5 RISKS RELATED TO THE COMMERCIALIZATION OF OUR PRODUCT CANDIDATES (36/264)GENSIGHT DDR 2017 VA - (37/264)GENSIGHT DDR 2017 VA - (38/264)GENSIGHT DDR 2017 VA - 4.6 RISKS RELATED TO OUR BUSINESS OPERATIONS (39/264)GENSIGHT DDR 2017 VA - (40/264)GENSIGHT DDR 2017 VA - (41/264)GENSIGHT DDR 2017 VA - (42/264)GENSIGHT DDR 2017 VA - (43/264)GENSIGHT DDR 2017 VA - (44/264)GENSIGHT DDR 2017 VA - 4.7 RISKS RELATED TO FINANCES AND TAXATION (45/264)GENSIGHT DDR 2017 VA - 4.8 LEGAL RISKS AND RISKS RELATED TO OUR INTELLECTUAL PROPERTY (46/264)GENSIGHT DDR 2017 VA - (47/264)GENSIGHT DDR 2017 VA - (48/264)GENSIGHT DDR 2017 VA - (49/264)GENSIGHT DDR 2017 VA - (50/264)GENSIGHT DDR 2017 VA - (51/264)GENSIGHT DDR 2017 VA - (52/264)GENSIGHT DDR 2017 VA - (53/264)GENSIGHT DDR 2017 VA - (54/264)GENSIGHT DDR 2017 VA - 4.9 MARKET RISKS (55/264)GENSIGHT DDR 2017 VA - 4.10 INSURANCE AND RISK MANAGEMENT (56/264)GENSIGHT DDR 2017 VA - (57/264)GENSIGHT DDR 2017 VA - (58/264)GENSIGHT DDR 2017 VA - (59/264)GENSIGHT DDR 2017 VA - 4.11 INTERNAL CONTROL AND RISK MANAGEMENT PROCEDURES (60/264)GENSIGHT DDR 2017 VA - 4.12 FINANCIAL RISK RELATED TO CLIMATE CHANGE (61/264)GENSIGHT DDR 2017 VA - (62/264)GENSIGHT DDR 2017 VA - INFORMATION ABOUT THE ISSUER (63/264)GENSIGHT DDR 2017 VA - 5.1 HISTORY AND DEVELOPMENT (64/264)GENSIGHT DDR 2017 VA - 5.2 INVESTMENTS (65/264)GENSIGHT DDR 2017 VA - (66/264)GENSIGHT DDR 2017 VA - BUSINESS OVERVIEW (67/264)GENSIGHT DDR 2017 VA - 6.1 OVERVIEW (68/264)GENSIGHT DDR 2017 VA - (69/264)GENSIGHT DDR 2017 VA - 6.2 OUR PRODUCT DEVELOPMENT PIPELINE - 6.3 OUR STRATEGY (70/264)GENSIGHT DDR 2017 VA - 6.4 GENE THERAPY IN THE EYE: A WELL-VALIDATED APPROACH (71/264)GENSIGHT DDR 2017 VA - 6.5 OUR LEAD PRODUCT CANDIDATE: GS010 FOR THE TREATMENT OF LHON (72/264)GENSIGHT DDR 2017 VA - (73/264)GENSIGHT DDR 2017 VA - (74/264)GENSIGHT DDR 2017 VA - (75/264)GENSIGHT DDR 2017 VA - (76/264)GENSIGHT DDR 2017 VA - (77/264)GENSIGHT DDR 2017 VA - 6.6 OUR SECOND PRODUCT CANDIDATE: GS030 FOR THE TREATMENT OF PHOTORECEPTOR DEGENERATION (78/264)GENSIGHT DDR 2017 VA - (79/264)GENSIGHT DDR 2017 VA - (80/264)GENSIGHT DDR 2017 VA - (81/264)GENSIGHT DDR 2017 VA - (82/264)GENSIGHT DDR 2017 VA - (83/264)GENSIGHT DDR 2017 VA - 6.7 LEVERAGING OUR PLATFORMS TO ADDRESS CENTRAL NERVOUS SYSTEM DISORDERS - 6.8 PHARMACO-ECONOMICS OF BLINDNESS AND VISUAL IMPAIRMENT (84/264)GENSIGHT DDR 2017 VA - 6.9 MANUFACTURING - 6.10 SALES AND MARKETING - 6.11 COMPETITION (85/264)GENSIGHT DDR 2017 VA - 6.12 GOVERNMENT REGULATION (86/264)GENSIGHT DDR 2017 VA - (87/264)GENSIGHT DDR 2017 VA - (88/264)GENSIGHT DDR 2017 VA - (89/264)GENSIGHT DDR 2017 VA - (90/264)GENSIGHT DDR 2017 VA - (91/264)GENSIGHT DDR 2017 VA - (92/264)GENSIGHT DDR 2017 VA - (93/264)GENSIGHT DDR 2017 VA - (94/264)GENSIGHT DDR 2017 VA - (95/264)GENSIGHT DDR 2017 VA - (96/264)GENSIGHT DDR 2017 VA - (97/264)GENSIGHT DDR 2017 VA - (98/264)GENSIGHT DDR 2017 VA - (99/264)GENSIGHT DDR 2017 VA - (100/264)GENSIGHT DDR 2017 VA - (101/264)GENSIGHT DDR 2017 VA - (102/264)GENSIGHT DDR 2017 VA - ORGANIZATIONAL CHART (103/264)GENSIGHT DDR 2017 VA - (104/264)GENSIGHT DDR 2017 VA - PROPERTY, PLANT AND EQUIPMENT (105/264)GENSIGHT DDR 2017 VA - 8.1 SIGNIFICANT EXISTING OR PLANNED PROPERTY, PLANT AND EQUIPMENT - 8.2 ENVIRONMENT AND SUSTAINABLE DEVELOPMENT (106/264)GENSIGHT DDR 2017 VA - (107/264)GENSIGHT DDR 2017 VA - (108/264)GENSIGHT DDR 2017 VA - (109/264)GENSIGHT DDR 2017 VA - (110/264)GENSIGHT DDR 2017 VA - (111/264)GENSIGHT DDR 2017 VA - (112/264)GENSIGHT DDR 2017 VA - OPERATING AND FINANCIAL REVIEW (113/264)GENSIGHT DDR 2017 VA - (114/264)GENSIGHT DDR 2017 VA - 9.1 Overview (115/264)GENSIGHT DDR 2017 VA - 9.2 Financial Operations Overview (116/264)GENSIGHT DDR 2017 VA - (117/264)GENSIGHT DDR 2017 VA - (118/264)GENSIGHT DDR 2017 VA - (119/264)GENSIGHT DDR 2017 VA - (120/264)GENSIGHT DDR 2017 VA - 9.3 Results of Operations (121/264)GENSIGHT DDR 2017 VA - (122/264)GENSIGHT DDR 2017 VA - (123/264)GENSIGHT DDR 2017 VA - (124/264)GENSIGHT DDR 2017 VA - CAPITAL RESOURCES (125/264)GENSIGHT DDR 2017 VA - 10.1 Overview - 10.2 Analysis of Cash Flow - 10.3 Funding Sources (126/264)GENSIGHT DDR 2017 VA - (127/264)GENSIGHT DDR 2017 VA - 10.4 Principal Uses of Cash (128/264)GENSIGHT DDR 2017 VA - (129/264)GENSIGHT DDR 2017 VA - (130/264)GENSIGHT DDR 2017 VA - RESEARCH AND DEVELOPMENT, PATENTS AND LICENSES (131/264)GENSIGHT DDR 2017 VA - 11.1 Overview - 11.2 Research and Development Expenditures (132/264)GENSIGHT DDR 2017 VA - 11.3 Medical and Scientific Committee (133/264)GENSIGHT DDR 2017 VA - 11.4 Collaboration, Partnership and Related Agreements (134/264)GENSIGHT DDR 2017 VA - (135/264)GENSIGHT DDR 2017 VA - 11.5 Intellectual Property (136/264)GENSIGHT DDR 2017 VA - (137/264)GENSIGHT DDR 2017 VA - (138/264)GENSIGHT DDR 2017 VA - (139/264)GENSIGHT DDR 2017 VA - (140/264)GENSIGHT DDR 2017 VA - (141/264)GENSIGHT DDR 2017 VA - (142/264)GENSIGHT DDR 2017 VA - TREND INFORMATION (143/264)GENSIGHT DDR 2017 VA - 12.1 Most Significant Recent Trends Since the End of the Last Financial Year - 12.2 Information on Any Known Trends, Uncertainties, Demands, Commitments or Events That Are Reasonably Likely to Have a Material Effect on the Company’s Prospects (144/264)GENSIGHT DDR 2017 VA - PROFIT FORECASTS OR ESTIMATES (145/264)GENSIGHT DDR 2017 VA - (146/264)GENSIGHT DDR 2017 VA - ADMINISTRATIVE, MANAGEMENT AND SUPERVISORY BODIES AND SENIOR MANAGEMENT (147/264)GENSIGHT DDR 2017 VA - 14.1 Composition of Management and Supervisory Bodies (148/264)GENSIGHT DDR 2017 VA - (149/264)GENSIGHT DDR 2017 VA - (150/264)GENSIGHT DDR 2017 VA - (151/264)GENSIGHT DDR 2017 VA - (152/264)GENSIGHT DDR 2017 VA - 14.2 Conflicts of Interest (153/264)GENSIGHT DDR 2017 VA - (154/264)GENSIGHT DDR 2017 VA - COMPENSATION AND BENEFITS (155/264)GENSIGHT DDR 2017 VA - 15.1 Compensation and Benefits of Senior Executives (156/264)GENSIGHT DDR 2017 VA - (157/264)GENSIGHT DDR 2017 VA - (158/264)GENSIGHT DDR 2017 VA - 15.2 Directors’ Compensation (159/264)GENSIGHT DDR 2017 VA - (160/264)GENSIGHT DDR 2017 VA - 15.3 Share Warrants, Share Warrants for Founders, STOCK OPTIONS and FREE Shares Granted to Senior Executives and Directors (161/264)GENSIGHT DDR 2017 VA - (162/264)GENSIGHT DDR 2017 VA - 15.4 History of Allocation of Share Warrants, Share Warrants for Founders and stock options (163/264)GENSIGHT DDR 2017 VA - (164/264)GENSIGHT DDR 2017 VA - 15.5 Share Warrants, Share Warrants for Founders or Stock Options of the Company Granted to the Company’s Top Ten Employees - 15.6 History of Allocation of Free Shares (165/264)GENSIGHT DDR 2017 VA - 15.7 Benefits of Senior Executives - 15.8 Compliance of Total Executive Director Compensation with the Recommendations of MiddleNext Code - 15.9 Amount of Provisions Made or Recorded by the Company for the Payment of Pensions, Retirement Plans or Other Benefits (166/264)GENSIGHT DDR 2017 VA - BOARD PRACTICES (167/264)GENSIGHT DDR 2017 VA - 16.1 Terms of Office of Members of the Corporate Bodies and Management Bodies - 16.2 Information on Service Contracts Between Members of the Administrative and Management Bodies and the Company - 16.3 Committees of the Board of Directors (168/264)GENSIGHT DDR 2017 VA - (169/264)GENSIGHT DDR 2017 VA - 16.4 Statement Relating to Corporate Governance (170/264)GENSIGHT DDR 2017 VA - (171/264)GENSIGHT DDR 2017 VA - 16.5 Operating principals of the Board of Directors (172/264)GENSIGHT DDR 2017 VA - EMPLOYEES (173/264)GENSIGHT DDR 2017 VA - 17.1 Human Resources Management - 17.2 Corporate Social Responsibility (174/264)GENSIGHT DDR 2017 VA - 17.3 Shareholdings and Share Warrants or Share Warrants for Founders Held by Members of the Board of Directors and Senior Management - 17.4 Employee Shareholding Plan and Long-Term Incentive Plans - 17.5 Profit-Sharing Agreements and Incentive Schemes (175/264)GENSIGHT DDR 2017 VA - (176/264)GENSIGHT DDR 2017 VA - MAJOR SHAREHOLDERS (177/264)GENSIGHT DDR 2017 VA - 18.1 Allocation of share capital (178/264)GENSIGHT DDR 2017 VA - (179/264)GENSIGHT DDR 2017 VA - 18.2 Shareholders’ Voting Rights - 18.3 Control Structure (180/264)GENSIGHT DDR 2017 VA - 18.4 Shareholders’ Agreement - 18.5 Agreements Likely to Lead to a Change of Control - 18.6 Lock-Up Agreement - 18.7 Pledges on Company’s Shares (181/264)GENSIGHT DDR 2017 VA - (182/264)GENSIGHT DDR 2017 VA - RELATED PARTY TRANSACTIONS (183/264)GENSIGHT DDR 2017 VA - 19.1 Agreements with the Company’s Major Shareholders - 19.2 Transactions with Key Management Persons (184/264)GENSIGHT DDR 2017 VA - 19.3 Statutory Auditor’s Report on Regulated Agreements and Commitments for the Fiscal Year Ending December 31, 2017 (185/264)GENSIGHT DDR 2017 VA - (186/264)GENSIGHT DDR 2017 VA - FINANCIAL INFORMATION CONCERNING THE GROUP’S ASSETS AND LIABILITIES, FINANCIAL POSITION AND PROFITS AND LOSSES (187/264)GENSIGHT DDR 2017 VA - 20.1 Historical Financial Information (188/264)GENSIGHT DDR 2017 VA - (189/264)GENSIGHT DDR 2017 VA - (190/264)GENSIGHT DDR 2017 VA - (191/264)GENSIGHT DDR 2017 VA - (192/264)GENSIGHT DDR 2017 VA - (193/264)GENSIGHT DDR 2017 VA - (194/264)GENSIGHT DDR 2017 VA - (195/264)GENSIGHT DDR 2017 VA - (196/264)GENSIGHT DDR 2017 VA - (197/264)GENSIGHT DDR 2017 VA - (198/264)GENSIGHT DDR 2017 VA - (199/264)GENSIGHT DDR 2017 VA - (200/264)GENSIGHT DDR 2017 VA - (201/264)GENSIGHT DDR 2017 VA - (202/264)GENSIGHT DDR 2017 VA - (203/264)GENSIGHT DDR 2017 VA - (204/264)GENSIGHT DDR 2017 VA - (205/264)GENSIGHT DDR 2017 VA - (206/264)GENSIGHT DDR 2017 VA - (207/264)GENSIGHT DDR 2017 VA - (208/264)GENSIGHT DDR 2017 VA - (209/264)GENSIGHT DDR 2017 VA - (210/264)GENSIGHT DDR 2017 VA - (211/264)GENSIGHT DDR 2017 VA - (212/264)GENSIGHT DDR 2017 VA - (213/264)GENSIGHT DDR 2017 VA - (214/264)GENSIGHT DDR 2017 VA - (215/264)GENSIGHT DDR 2017 VA - 20.2 Date of Latest Financial Information - 20.3 Historical Financial Information for The Fiscal Years Ending December 31, 2015 and 2016 - 20.4 Dividend Policy - 20.5 Legal and Arbitration Proceedings - 20.6 Significant Change in Financial or Trading Position (216/264)GENSIGHT DDR 2017 VA - ADDITIONAL INFORMATION (217/264)GENSIGHT DDR 2017 VA - 21.1 Share Capital (218/264)GENSIGHT DDR 2017 VA - (219/264)GENSIGHT DDR 2017 VA - (220/264)GENSIGHT DDR 2017 VA - (221/264)GENSIGHT DDR 2017 VA - (222/264)GENSIGHT DDR 2017 VA - (223/264)GENSIGHT DDR 2017 VA - (224/264)GENSIGHT DDR 2017 VA - (225/264)GENSIGHT DDR 2017 VA - (226/264)GENSIGHT DDR 2017 VA - (227/264)GENSIGHT DDR 2017 VA - 21.2 Constitutive Documents and Bylaws (228/264)GENSIGHT DDR 2017 VA - (229/264)GENSIGHT DDR 2017 VA - (230/264)GENSIGHT DDR 2017 VA - (231/264)GENSIGHT DDR 2017 VA - (232/264)GENSIGHT DDR 2017 VA - MATERIAL CONTRACTS (233/264)GENSIGHT DDR 2017 VA - 22.1 Collaboration, Partnership and Related Agreements (234/264)GENSIGHT DDR 2017 VA - 22.2 In-License Agreements - 22.3 Manufacturing Agreement (235/264)GENSIGHT DDR 2017 VA - (236/264)GENSIGHT DDR 2017 VA - THIRD PARTY INFORMATION AND STATEMENT BY EXPERTS AND DECLARATIONS OF ANY INTEREST (237/264)GENSIGHT DDR 2017 VA - (238/264)GENSIGHT DDR 2017 VA - DOCUMENTS ON DISPLAY (239/264)GENSIGHT DDR 2017 VA - (240/264)GENSIGHT DDR 2017 VA - INFORMATION ON EQUITY INTERESTS (241/264)GENSIGHT DDR 2017 VA - (242/264)GENSIGHT DDR 2017 VA - GLOSSARY (243/264)GENSIGHT DDR 2017 VA - (244/264)GENSIGHT DDR 2017 VA - ANNEXES (245/264)GENSIGHT DDR 2017 VA - ANNEX 1. COMPANY’S ANNUAL FINANCIAL STATEMENTS (FRENCH-GAAP) FOR THE FISCAL YEAR ENDING DECEMBER 31, 2017 - 1. BALANCE SHEET ASSETS - ANNEX 1 COMPANY’S ANNUAL FINANCIAL STATEMENTS (FRENCH-GAAP) FOR THE FISCAL YEAR ENDING DECEMBER 31, 2017 (246/264)GENSIGHT DDR 2017 VA - (247/264)GENSIGHT DDR 2017 VA - 2. STATEMENTS OF INCOME (LOSS) (248/264)GENSIGHT DDR 2017 VA - 3. NOTES TO THE FINANCIAL STATEMENTS (249/264)GENSIGHT DDR 2017 VA - (250/264)GENSIGHT DDR 2017 VA - (251/264)GENSIGHT DDR 2017 VA - (252/264)GENSIGHT DDR 2017 VA - (253/264)GENSIGHT DDR 2017 VA - (254/264)GENSIGHT DDR 2017 VA - (255/264)GENSIGHT DDR 2017 VA - (256/264)GENSIGHT DDR 2017 VA - (257/264)GENSIGHT DDR 2017 VA - (258/264)GENSIGHT DDR 2017 VA - ANNEX 2 OTHER INFORMATION RELATING TO THE FINANCIAL STATEMENTS OF GENSIGHT BIOLOGICS S.A. PARENT COMPANY - ANNEX 2 OTHER INFORMATION RELATING TO THE FINANCIAL STATEMENTS OF GENSIGHT BIOLOGICS S.A. PARENT COMPANY (259/264)GENSIGHT DDR 2017 VA - ANNEX 3 STATUTORY AUDITOR’S REPORT ON THE COMPANY’S ANNUAL FINANCIAL STATEMENTS (FRENCH GAAP) FOR THE FISCAL YEAR ENDING DECEMBER 31, 2017 - ANNEX 3 STATUTORY AUDITOR’S REPORT ON THE COMPANY’S ANNUAL FINANCIAL STATEMENTS (FRENCH GAAP) FOR THE FISCAL YEAR ENDING DECEMBER 31, 2017 (260/264)GENSIGHT DDR 2017 VA - (261/264)GENSIGHT DDR 2017 VA - (262/264)GENSIGHT DDR 2017 VA - (263/264)GENSIGHT DDR 2017 VA - (264/264) ORGANIZATIONAL CHART 7 On April 28, 2017, the Company incorporated its first subsidiary, GenSight Biologics Inc., a Delaware corporation, registered and located in the United States of America. This U.S.-based subsidiary is wholly owned by GenSight Biologics S.A.. 102– GENSIGHT BIOLOGICS – 2017 Registration Document